Comments
Zydus Cadila has received final approval from the US health regulator to market indomethacin extended release capsules used in treating painful and inflammatory conditions such as arthritis.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 75 mg, it said in a BSE filing today.
Zydus Cadila will manufacture the drug at the Moraiya facility in Ahmedabad.
Zydus Cadila said it has more than 155 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it had commenced filings in 2003-04.
Shares of the company’s listed entity Cadila Healthcare were trading down by 3.07 per cent at Rs 459.75 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.